Ongoing care: The membership supports follow-up, dose management, and progress monitoring
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
In a 3-month randomized controlled study of type 2 diabetes, it was found that the combination of liraglutide and sitagliptin had no effect on the composition of intestinal flora, had no effect on the alpha and beta diversity, but liraglutide resulted in an elevation of deoxycholic acid (DCA) levels, indicating potential modulation of bile acid metabolism (Smits et al., 2021)
New GLP-1
If you notice a reaction that is severe, gets worse, or doesn't go away, be sure to contact your healthcare provider
Twenty-four-hour blood pressure-lowering effect of a Sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study